| West Hills Health And Rehabilitation Center | |
| 951 Brodhead Road, Coraopolis, Pennsylvania 15108 | |
| (412) 269-1101 | |
| Name | West Hills Health And Rehabilitation Center |
|---|---|
| Location | 951 Brodhead Road, Coraopolis, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 150 |
| Occupancy Rate | 60.33% |
| Medicare ID (CCN) | 395620 |
| Legal Business Name | Ssc Coraopolis Operating Company Lp |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1225776214 |
| Organization Name | CORAOPOLIS REHABILITATION AND WELLNESS CENTER LLC |
| Address | 951 Brodhead Rd, Coraopolis, PA 15108 |
| Phone Number | 412-269-1101 |
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.
Avalon Healthcare Solutions today announced a second round of investment from Francisco Partners. The incremental capital will be used to enhance Avalon's comprehensive laboratory management technology and clinical capabilities, as well as to strengthen growth opportunities.
Pursuant to the previously announced merger agreement entered into to acquire American Pacific Corporation (NASDAQ: APFC) (the "Company"), H.I.G. Capital, LLC ("H.I.G.") today announced that Flamingo Merger Sub Corp. ("Purchaser") has commenced a cash tender offer to acquire any and all of the outstanding shares of the Company's common stock.
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.
› Verified 2 days ago
| NPI Number | 1508636010 |
| Organization Name | CEDAR HILL HEALTHCARE LLC |
| Address | 951 Brodhead Rd, Coraopolis, PA 15108 |
| Phone Number | 412-269-1101 |
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.
Avalon Healthcare Solutions today announced a second round of investment from Francisco Partners. The incremental capital will be used to enhance Avalon's comprehensive laboratory management technology and clinical capabilities, as well as to strengthen growth opportunities.
Pursuant to the previously announced merger agreement entered into to acquire American Pacific Corporation (NASDAQ: APFC) (the "Company"), H.I.G. Capital, LLC ("H.I.G.") today announced that Flamingo Merger Sub Corp. ("Purchaser") has commenced a cash tender offer to acquire any and all of the outstanding shares of the Company's common stock.
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.
› Verified 2 days ago
| NPI Number | 1548381031 |
| Organization Name | SSC CORAOPOLIS OPERATING COMPANY LP |
| Doing Business As | WEST HILLS HEALTH AND REHABILITATION CENTER |
| Address | 951 Brodhead Rd, Coraopolis, PA 15108 |
| Phone Number | 412-269-1101 |
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.
Avalon Healthcare Solutions today announced a second round of investment from Francisco Partners. The incremental capital will be used to enhance Avalon's comprehensive laboratory management technology and clinical capabilities, as well as to strengthen growth opportunities.
Pursuant to the previously announced merger agreement entered into to acquire American Pacific Corporation (NASDAQ: APFC) (the "Company"), H.I.G. Capital, LLC ("H.I.G.") today announced that Flamingo Merger Sub Corp. ("Purchaser") has commenced a cash tender offer to acquire any and all of the outstanding shares of the Company's common stock.
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.
Avalon Healthcare Solutions today announced a second round of investment from Francisco Partners. The incremental capital will be used to enhance Avalon's comprehensive laboratory management technology and clinical capabilities, as well as to strengthen growth opportunities.
Pursuant to the previously announced merger agreement entered into to acquire American Pacific Corporation (NASDAQ: APFC) (the "Company"), H.I.G. Capital, LLC ("H.I.G.") today announced that Flamingo Merger Sub Corp. ("Purchaser") has commenced a cash tender offer to acquire any and all of the outstanding shares of the Company's common stock.
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.9 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 17.88 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50.67 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.24 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.35 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.21 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.32 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.24 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 8.53 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.74 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.98 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 38.21 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 19.32 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 12.82 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.24 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 65.48 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.85 | 82.93 |
News Archive
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes.
Avalon Healthcare Solutions today announced a second round of investment from Francisco Partners. The incremental capital will be used to enhance Avalon's comprehensive laboratory management technology and clinical capabilities, as well as to strengthen growth opportunities.
Pursuant to the previously announced merger agreement entered into to acquire American Pacific Corporation (NASDAQ: APFC) (the "Company"), H.I.G. Capital, LLC ("H.I.G.") today announced that Flamingo Merger Sub Corp. ("Purchaser") has commenced a cash tender offer to acquire any and all of the outstanding shares of the Company's common stock.
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that can cause vision loss.
› Verified 2 days ago
Caring Heights Community Care & Rehab Ctr Location: 234 Coraopolis Road, Coraopolis, Pennsylvania 15108 Phone: (412) 331-6060 | |
West Hills Health And Rehabilitation Center Location: 951 Brodhead Road, Coraopolis, Pennsylvania 15108 Phone: (412) 269-1101 |